A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Terminated · Phase 3 · NCT04752332
Conditions: Breast Neoplasms
At a glance
- Research payments reported, 2025
- $46,374
- U.S. investigators named
- 11
- Sites paid
- 9
- Planned or actual enrollment
- 111
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Standard Adjuvant ET (drug), Placebo (drug)
- Dates
- Started 2021-05-10; completion 2024-06-26
- Results posted
- Yes
The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.
From ClinicalTrials.gov, last updated 2025-07-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $46,374 in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Carlos A. Alemany, M.D. Hematology & Oncology · Orlando, FL
- Venkat Pavan R. Kancharla, M.D Medical Oncology · Palm Bay, FL
- Gail L. Wright, M.D. Medical Oncology · New Port Richey, FL
- Rami Y. Haddad, MD Hematology & Oncology · Oak Lawn, IL
- Paramjeet G. Khosla, M.D. Hematology & Oncology · Chicago, IL
- Leonard M. Klein Hematology & Oncology · Niles, IL
- Bharat H. Barai, M.D. Hematology & Oncology · Merrillville, IN
- Jay C. Andersen, M.D. Hematology & Oncology · Portland, OR
- Emmalind Aponte, MD Hematology & Oncology · San Antonio, TX
- Jay G. Courtright, M.D. Medical Oncology · Dallas, TX
- Alvaro Restrepo, MD Medical Oncology · Mcallen, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Adventhealth Orlando, FL $19,585
- Prisms Group LLC $15,150
- Texas Oncology PA $5,234
- Sarah Cannon Research Institute LLC $1,982
- Northwest Cancer Specialists PC $1,547
- Affiliated Oncologists - Southland Oncology $956
- Illinois Cancer Specialists PC $956
- Cancer Care Centers of Brevard, Inc. $956
- Florida Cancer Specialists $8
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.